SEPOY.net
No Result
View All Result
Thursday, June 19, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Gout medicine fails to improve cardiovascular outcomes in patients with ischemic heart disease

Nicholas by Nicholas
August 28, 2022
in Health
0

The gout medicine allopurinol has failed to reduce the primary endpoint of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death in patients with ischemic heart disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.

READ ALSO

UTA receives grant to tackle low physical activity among cancer survivors

New dual-adjuvant vaccine strategy offers hope in the fight against HIV

Allopurinol is a xanthine oxidase inhibitor that lowers uric acid and is used to treat patients with gout. Previous studies have shown that the drug also has cardiovascular benefits. For example, in patients with angina and coronary artery disease, allopurinol increased exercise time and reduced chest pain, suggesting anti-ischemic activity.

The ALL-HEART study investigated whether allopurinol therapy improves major cardiovascular outcomes in patients with ischemic heart disease. The study included patients aged 60 years or older with ischemic heart disease but no history of gout. Patients were randomized 1:1 to receive allopurinol up-titrated to a dose of 600 mg daily plus usual care or usual care alone. The average age was 72 years and 76% were men. Participants were followed up by record linkage and annual questionnaires. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death.

The modified intention-to-treat analysis population included 5,721 randomized patients, of which 2,853 were in the allopurinol arm and 2,868 were in the usual care arm. The mean follow up was 4.8 years. There was no difference between groups in the rate of the primary endpoint, which occurred in 314 (11.0%) participants in the allopurinol arm (2.47 events per 100 patient years) and 325 (11.3%) in the usual care arm (2.37 events per 100 patient years), giving a hazard ratio (HR) of 1.04 (95% confidence interval [CI] 0.89-1.21, p=0.65).

There were also no differences between groups in any of the secondary time to event outcomes, which included nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, all-cause mortality, hospitalisation for acute coronary syndrome (ACS), coronary revascularization, hospitalization for ACS or coronary revascularization, hospitalization for heart failure, and all cardiovascular hospitalizations. A total of 288 (10.1%) patients in the allopurinol arm died compared with 303 (10.6%) patients in the usual care arm, giving a HR of 1.02 (95% CI 0.87-1.20, p=0.77).

The ALL-HEART study has shown that allopurinol therapy does not improve major cardiovascular outcomes in patients with ischemic heart disease. Allopurinol is already widely used in patients with gout to prevent acute flares, and many of these patients have co-existing ischemic heart disease. The question of whether allopurinol might prevent cardiovascular events in people with heart disease but no clinical gout has been around for many years and we are pleased to have now definitively answered this question for patients and doctors in a robust study.”

Isla Mackenzie, Principal Investigator, Professor, University of Dundee, UK

Source:

European Society of Cardiology (ESC)

Tags: AllopurinolCardiologyGoutHeartHeart DiseaseMedicineMyocardial InfarctionResearchStrokeUric Acid

Related Posts

UTA receives grant to tackle low physical activity among cancer survivors
Health

UTA receives grant to tackle low physical activity among cancer survivors

June 19, 2025
New dual-adjuvant vaccine strategy offers hope in the fight against HIV
Health

New dual-adjuvant vaccine strategy offers hope in the fight against HIV

June 19, 2025
Smoking leaves lasting marks in teeth even after quitting
Health

Smoking leaves lasting marks in teeth even after quitting

June 19, 2025
Kupffer cell reprogramming in embryos explains metabolic disorders in offspring
Health

Kupffer cell reprogramming in embryos explains metabolic disorders in offspring

June 18, 2025
Immune cell signatures explain variations in systemic sclerosis severity
Health

Immune cell signatures explain variations in systemic sclerosis severity

June 18, 2025
Gut microbiome resists major changes from a nut-rich diet
Health

Gut microbiome resists major changes from a nut-rich diet

June 18, 2025
Next Post

Trump on the FBI Raid: Maximum Attention

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Position Crystal Sunrays Play Totally free Game On Gold of Persia slot free spins the web instead of Getting
  • Amazingly Sun best 2 reel slots Slot Gamble On the internet
  • Crystal Sunlight Play’n play Sparks Rtp slot online no download Go Slot Evaluation & Demo

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net